What the changes say
- LENZ transitioned from a clinical-stage biotech to a commercial-stage company following FDA approval and U.S. launch of VIZZ for presbyopia.
What changed since the prior 10-K
New
- NewRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
Our business depends entirely on the development and commercialization of VIZZ and we do not have additional product candidates in our current development pipeline. If we are unable to successfully commercialize VIZZ, our business will be materially harmed
Our success depends entirely on VIZZ, our sole FDA-approved product for presbyopia, as we lack other candidates in our pipeline.
- NewRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
VIZZ may fail to achieve market acceptance by ECPs and patients, and the market opportunity for VIZZ may be smaller than we estimate
VIZZ may struggle to gain market acceptance because presbyopia is typically managed with reading glasses and requires an ECP visit for a prescription.
- NewRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product on acceptable terms, we may be unable to successfully commercialize our product. In addition, our intended sales strategies may be unsuccessful and/or more costly than anticipated
Building and expanding our internal sales and marketing infrastructure for VIZZ is expensive, time-consuming, and diverts executive management.
- NewRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
in VIZZ, has been marketed in more than 12 countries throughout Europe for the treatment of glaucoma by decreasing intraocular pressure
European generic aceclidine for glaucoma and off-label uses like Glaucostat could create competition and supply issues that harm VIZZ profitability.
- NewRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
While VIZZ received FDA approval in July 2025, we may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of foreign regulatory authorities, that VIZZ or any future product candidates are safe and effective for their intended uses
Foreign regulatory authorities may not accept VIZZ trial data, and unexpected side effects could force additional clinical studies or limit sales.
- NewRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
we submit to the FDA. To the extent any executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted
Executive actions constraining FDA oversight or penalties for off-label promotional claims could disrupt our commercialization and generate negative publicity.
- NewRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our products, and prevent us from being able to generate revenue, attain profitability or commercialize our products
Healthcare cost containment, legislative reforms, and federal or state fraud and abuse laws could constrain VIZZ pricing and reduce our earnings.
- NewRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
regulations addressing specific subject matter, such as Washington’s My Health, My Data Act, which, among other things, provides for a private right of action
Privacy and cybersecurity laws, including Washington’s My Health, My Data Act, increase our compliance costs and expose us to private litigation.
- NewRisks Related to Our Common Stock
Sales of a substantial number of shares of our common stock by holders of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock
Public market sales of common stock registered under prior PIPE financings could depress the market price of our stock.
Dropped
- DroppedRisks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates
our business will be materially harmed. We currently generate no revenue from sales of any products and may never generate revenue or be profitable
- DroppedRisks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates
Even if LNZ100 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, and the market opportunity for these products, if approved, may be smaller than we estimate
Zero revenue and anticipated PDUFA target action date of August 8, 2025.
- DroppedRisks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates
If we experience delays or difficulties in the enrollment and/or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
- DroppedRisks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates
Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
Market acceptance uncertainty for LNZ100 and other product candidates.
- DroppedRisks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates
LNZ100 may not demonstrate sufficient additional clinical benefits to ECPs, patients or payors to justify a higher price compared to using glasses, which are potentially just a one-time purchase
Clinical trial enrollment and retention delays.
- DroppedRisks Related to Our Intellectual Property
agreements. Any of these events could adversely affect our business, financial condition, results of operations, and prospects
Risks from changes in manufacturing methods or formulation.
- DroppedRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
Additional time may be required to develop and obtain regulatory approval for LNZ100 because we expect it will be regulated as a drug-device combination product
LNZ100 clinical benefit pricing justification versus glasses.
- DroppedRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
company and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved
- DroppedRisks Related to Our Reliance on Third Parties
future dependence upon others for the manufacture of LNZ100 may adversely affect our future profit margins and our ability to commercialize LNZ100, if approved, on a timely and competitive basis
- DroppedRisks Related to Our Reliance on Third Parties
We entered into a collaboration agreement with CORXEL and depend on CORXEL to develop and commercialize its products within Greater China. We have limited control over how CORXEL will conduct development and commercialization activities for LNZ100 or LNZ101
- DroppedRisks Related to Our Common Stock
On April 9, 2024, we filed a registration statement on Form S-1 to register the offer and sale of 1,297,411 shares of common stock issued in the March 2024 PIPE Financing, and on April 10, 2024, that registration statement was declared effective by the SEC
- DroppedRisks Related to Our Common Stock
Transfers of our securities utilizing Rule 144 of the Securities Act may be limited
Reworded
- 100% rewrittenRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and ability to achieve and maintain profitability
Shifted focus from clinical development status to operating losses impacting working capital and profitability following the VIZZ commercial launch.
- 100% rewrittenRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
VIZZ is based on an active pharmaceutical ingredient (“API”), aceclidine, that has been previously approved and marketed outside of the U.S., which exposes us to additional risks
Updated to reflect VIZZ obtaining five years of U.S. NCE exclusivity expiring in July 2030.
Was: Our current product candidate, LNZ100, is based on an active pharmaceutical ingredient (“API”) that has been previously approved and marketed outside of the United States, which exposes us to additional risks
- 90% rewrittenRisks Related to Our Reliance on Third Parties
The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of VIZZ for patients could be delayed or prevented
Updated heading and text to explicitly focus on third-party manufacturing difficulties and their impact on VIZZ supply.
Was: The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of LNZ100 for patients, if approved, could be delayed or prevented
- 67% rewrittenRisks Related to Our Common Stock
The disposal of Graphite’s historical assets and operations in connection with the Merger made us subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we will be subject to more stringent reporting requirements, offering limitations, and resale restrictions
Added specific references to Graphite's historical asset disposal and resulting shell company reporting requirements.
- 55% rewrittenRisks Related to Our Common Stock
Our ability to use net operating loss carryforwards and other tax attributes may be limited
Updated federal and state NOL carryforwards to $178.9 million and $12.4 million as of December 31, 2025.
Was: Our ability to use net operating loss carryforwards and other tax attributes may be limited, including those obtained as a result of the Merger
- 55% rewrittenRisks Related to Our Intellectual Property
If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product or future product candidates
Expanded third-party agreement risk scope from future candidates to current products and product candidates.
Was: If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates
- 50% rewrittenRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
Refined healthcare legislative and regulatory risk language regarding potential impacts on product labeling and recall requirements.
- 41% rewrittenRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
Added explicit mention that VIZZ is currently only approved for commercial sale in the U.S.
- 31% rewrittenRisks Related to Our Limited Operating History and Commercialization of Our Product Candidates
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of VIZZ
Was: If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, if approved
- 30% rewrittenRisks Related to Our Common Stock
The market price of our common stock is expected to be volatile, and the market price of the common stock may drop
- 29% rewrittenRisks Related to Our Regulatory Approval and Other Legal Compliance Matters
Restrictive laws and regulations govern the collection, use, transfer, and other processing of personal information
- 28% rewrittenRisks Related to Our Common Stock
We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition
- 21% rewrittenRisks Related to Our Intellectual Property
We may not be able to protect our intellectual property rights throughout the world, which could impair our business
All 53 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Limited Operating History and Commercialization of Our Product Candidates
- 01Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and ability to achieve and maintain profitability100% rewritten
- 02Our business depends entirely on the development and commercialization of VIZZ and we do not have additional product candidates in our current development pipeline. If we are unable to successfully commercialize VIZZ, our business will be materially harmedNew
- 03VIZZ may fail to achieve market acceptance by ECPs and patients, and the market opportunity for VIZZ may be smaller than we estimateNew
- 04If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product on acceptable terms, we may be unable to successfully commercialize our product. In addition, our intended sales strategies may be unsuccessful and/or more costly than anticipatedNew
- 05We may need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all
- 06VIZZ is based on an active pharmaceutical ingredient (“API”), aceclidine, that has been previously approved and marketed outside of the U.S., which exposes us to additional risks100% rewritten
- 07in VIZZ, has been marketed in more than 12 countries throughout Europe for the treatment of glaucoma by decreasing intraocular pressureNew
- 08While VIZZ received FDA approval in July 2025, we may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of foreign regulatory authorities, that VIZZ or any future product candidates are safe and effective for their intended usesNew
- 09If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of VIZZ31% rewritten
- 10A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
- 11These and other risks associated with our international operations or those of any applicable international partners may materially adversely affect our ability to attain or maintain profitable operations
Risks Related to Our Intellectual Property
- 12Patent terms may be inadequate to protect our competitive position on our product and product candidates for an adequate amount of time
- 13Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
- 14We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
- 15We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization of VIZZ and any future product candidate
- 16Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
- 17Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product or any future product candidates
- 18We may not be able to protect our intellectual property rights throughout the world, which could impair our business21% rewritten
- 19If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
- 20We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property
- 21If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
- 22Intellectual property rights do not necessarily address all potential threats to our competitive advantage
- 23Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current or future product candidates
- 24If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product or future product candidates55% rewritten
- 25In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities
- 26We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties
Risks Related to Our Regulatory Approval and Other Legal Compliance Matters
- 27Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions41% rewritten
- 28we submit to the FDA. To the extent any executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impactedNew
- 29We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations50% rewritten
- 30The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our products, and prevent us from being able to generate revenue, attain profitability or commercialize our productsNew
- 31Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
- 32If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
- 33We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and can face serious consequences for violations
- 34Restrictive laws and regulations govern the collection, use, transfer, and other processing of personal information29% rewritten
- 35regulations addressing specific subject matter, such as Washington’s My Health, My Data Act, which, among other things, provides for a private right of actionNew
Risks Related to Our Reliance on Third Parties
- 36The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of VIZZ for patients could be delayed or prevented90% rewritten
Risks Related to Our Business Operations
- 37Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
- 38If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks
- 39We expect to significantly expand our organization, including building sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
- 40We could be subject to securities class action litigation, which is expensive and could divert management attention
Risks Related to Our Common Stock
- 41An active trading market for our common stock may never develop or be sustained
- 42The market price of our common stock is expected to be volatile, and the market price of the common stock may drop30% rewritten
- 43Sales of a substantial number of shares of our common stock by holders of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stockNew
- 44Our board of directors is authorized to issue and designate shares of our convertible preferred stock in additional series without stockholder approval
- 45We will continue to be an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
- 46If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
- 47Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
- 48Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us
- 49The disposal of Graphite’s historical assets and operations in connection with the Merger made us subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we will be subject to more stringent reporting requirements, offering limitations, and resale restrictions67% rewritten
- 50If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline
- 51We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition28% rewritten
- 52Our ability to use net operating loss carryforwards and other tax attributes may be limited55% rewritten
- 53Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations, or cash flows
Other LENZ Therapeutics 10-Ks
- FY2024 10-K risk factors56 risks
LENZ Therapeutics relies entirely on the success of LNZ100 for presbyopia, pending FDA review of its NDA submitted in August 2024. The company depends on third-party manufacturers, international partners like CORXEL in Greater China, and robust intellectual property protection for aceclidine.
Filed Mar 19, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.